Most traditional cytotoxic anticancer agents ablate the rapidly dividing epithelium of the hair follicle and induce alopecia (hair loss). Inhibition of cyclindependent kinase 2 (CDK2), a positive regulator of eukaryotic cell cycle progression, may represent a therapeutic strategy for prevention of chemotherapyinduced alopecia (CIA) by arresting the cell cycle and reducing the sensitivity of the epithelium to many cell cycle-active antitumor agents. Potent smallmolecule inhibitors of CDK2 were developed using structure-based methods. Topical application of these compounds in a neonatal rat model of CIA reduced hair loss at the site of application in 33 to 50% of the animals. Thus, inhibition of CDK2 represents a potentially useful approach for the prevention of CIA in cancer patients.
Most traditional cytotoxic anticancer agents ablate the rapidly dividing epithelium of the hair follicle and induce alopecia (hair loss). Inhibition of cyclindependent kinase 2 (CDK2), a positive regulator of eukaryotic cell cycle progression, may represent a therapeutic strategy for prevention of chemotherapyinduced alopecia (CIA) by arresting the cell cycle and reducing the sensitivity of the epithelium to many cell cycle-active antitumor agents. Potent smallmolecule inhibitors of CDK2 were developed using structure-based methods. Topical application of these compounds in a neonatal rat model of CIA reduced hair loss at the site of application in 33 to 50% of the animals. Thus, inhibition of CDK2 represents a potentially useful approach for the prevention of CIA in cancer patients.
Chemotherapy-induced alopecia (CIA) is a frequent and emotionally distressing side effect of cancer chemotherapy (1, 2) for which there is currently no effective preventive therapy (3, 4) . CIA is thought to arise when anticancer drugs ablate the proliferating epithelium and block normal maturation of precursor epithelial cells to the final hair strand product (5) .
The sensitivity of hair follicle cells to anticancer agents is related to their state of proliferation. Many anticancer agents that cause CIA target specific phases of the cell cycle and are therefore selectively toxic to cells undergoing division (6) . Inhibition of cell cycle progression has been shown to decrease the cytotoxic activity of cell cycleactive cytotoxic drugs (7) . CDK2, a member of the protein kinase family that orchestrates the orderly progression of the eukaryotic cell cycle (8) , plays a key role from late G 1 to late G 2 (9) . We postulated that inhibition of CDK2 might provide the required control over cell division in the hair follicle to prevent CIA.
Here, we describe a class of synthetic CDK inhibitors, represented by structure 1 (Fig. 1A) , which inhibit the enzyme by competing with adenosine triphosphate (ATP). As part of an ongoing effort to identify selective kinase inhibitors, we examined analogs of the 3-(benzylidene)indolin-2-ones 2. These compounds inhibit receptor tyrosine kinases, such as epidermal growth factor receptor and Her-2 receptor kinases (10). Compound 3, prepared as a homolog of compound 2, was found to selectively inhibit CDK2 (median inhibitory concentration IC 50 ϭ 60 nM) and served as the lead compound for the work described here.
Structure-based methods were used to design analogs of compound 3. CDK2 and its complexes with ATP (11), cyclin A (12), and small-molecule inhibitors (13) have been studied extensively by x-ray crystallography. To evaluate and select potential analogs of compound 3, we determined the crystal structure of 3 bound to CDK2 (Fig. 1B) (14) .
Analysis of the CDK2-compound 3 structure provided the basis for analog design. For example, position 5 of the inhibitor is adjacent to the amino group of Lys 33 , which suggests that hydrogen bond acceptors at that position might enhance affinity for the enzyme. Similarly, lipophilic substituents at position 4 would be expected to contribute to binding through interactions with nearby hydrophobic residues such as Val 18 . In addition, the orientation of the sulfonamide functionality at the opening to the binding cleft suggested that substituents on the sulfonamide might have minimal interaction with the protein. This knowledge can be exploited to alter other compound properties, such as pharmacokinetic and solubility characteristics, without negatively affecting enzyme binding.
Compound 4, designed according to the above approach, was a potent and selective inhibitor of CDK2 (IC 50 ϭ 10 nM), a weaker inhibitor of CDK1 and CDK4 (IC 50 ϭ 110 and 130 nM, respectively), and a significantly weaker inhibitor of 12 other diverse protein kinases (average IC 50 ϭ 2 M). A crystal structure of compound 4 in complex with CDK2-cyclin A confirmed the inhibitor binding mode and the expected interactions between protein and ligand (Fig. 1C) .
The effects of compound 4 and related analogs on cell cycle progression were initially evaluated in a cell-based assay that assessed the ability of the compound to block progress from late G 1 into S phase of the cell cycle. Treatment of synchronized human diploid fibroblast (HDF) cells with compound 4 caused a reduction in bromodeoxyuridine (BrdU) incorporation into cellular DNA (IC 50 ϭ 2.5 M). Flow cytometric analysis of asynchronous HDF cells was used to measure cell cycle progression, DNA synthesis, and apoptosis (15). Compound 4 (7.5 M) exposure did not change the percentage of cells in G 1 and G 2 -M phases of the cell cycle ( Fig. 2A) . However, compound 4 blocked S phase progression, as shown by the reduced amount of BrdU per cell and by the decreased percentage of BrdUpositive cells at 6 hours and 24 hours (Fig. 2B) . The effects on the cell cycle were reversible; cells resumed DNA synthesis upon compound withdrawal, as shown by the increased percentage of BrdU-positive cells at 2 hours and 18 hours after compound removal (Fig. 2B ). Compound 4 did not increase the number of cells containing Ͻ2N DNA, a measure of apoptosis, which suggests that it did not induce apoptosis.
Compound 4 also inhibited the phosphorylation of retinoblastoma (Rb) protein, a CDK2 substrate. Rb is a key regulator of progression of cells from G 1 into S and through S phase (16) . Hypo-and hyperphosphorylated forms of the Rb protein were visualized by Western analysis. Treatment of HDFs with compound 4 changed the status of Rb from the hyper-to hypophosphorylated state at 6 hours and 24 hours (15), and the reduction of Rb phosphorylation correlated with cell cycle arrest. In addition, cyclin A protein, whose expression is required for S phase and is positively controlled by CDK2-cyclin E catalytic activity, was down-regulated after compound treatment (15, 17) . A similar reduction in cyclin A mRNA levels was observed. Compound 4 treatment did not change the protein levels of either CDK2 or cyclin E (15, 18). These data are consistent with inhibition of CDK2 catalytic activity and with the sequential order of cyclin E and cyclin A expression during cell cycle progression.
Pretreatment of HDF cells with compound 4 (10 M) inhibited apoptosis induced by etoposide (Fig. 2C) , as evidenced by the reduction in the number of cells containing Ͻ2N DNA. Similar results were observed for additional substituted oxindole compounds and for olomoucine (150 M), a CDK2 inhibitor that is structurally distinct from the substituted oxindoles and considerably less potent against the CDK2 enzyme (IC 50 ϳ7 M) (19) . We also studied the effect of compound 4 on cytotoxicity of a panel of clinical anticancer agents with both cell cycle-dependent [5-fluorouracil (5FU) (S), etoposide (S and G 2 ), and taxol (M)] and cell cycle-independent (cisplatin and doxorubicin) mechanisms of action. CCL64 mink lung epithelial cells are sensitive to a variety of anticancer agents and were used for these studies (20) . Compound 4 (12 M) reduced the cytotoxicity of taxol, etoposide, cisplatin, 5FU, and doxorubicin by factors of 5, 1.5, 8, 4, and 5, respectively (Fig. 2D) . Thus, compound 4 effectively protected cells from a panel of cytotoxic agents that have diverse mechanisms of action. These data suggest that compound 4 may exert its pharmacological effects through an antiapoptotic mechanism, as has been shown previously for CDK2 inhibition (21) . However, we cannot exclude the possibility that inhibition of additional CDKs (CDK1 and CDK4) may play a key role in the cytoprotective effects observed.
An animal model of human hair growth was used to test whether the epithelium of the hair follicle was sensitive to growth arrest by CDK2 inhibitor (15, 22) . In this model, fresh human scalp samples are transplanted onto the skin of severe combined immunodeficient (SCID) mice (Fig. 3A) . Topical treatment with compound 4 formulated in dimethyl sulfoxide (DMSO) reduced the BrdU-positive nuclear labeling index by a factor of 3 at 6 hours after treatment (Fig.  3B) . The antiproliferative effect was reversible; the fraction of S-phase cells returned to control values 18 hours after topical dosing. Bright-field microscopic analysis of a skin biopsy specimen from a compound 4-treated animal showed a reduction in the BrdU-positive cells in the epithelium of the hair follicle (Fig. 3, C and D) . A similar profile was observed in rat skin (15). These data illustrate that the compound reached the target cell population in the hair follicle and produced the desired inhibitory effects on cell cycle progression.
The in vivo efficacy of compound 4 was studied in a neonatal rat model of CIA (23) . Two alopecia drug regimens were studied: etoposide and cyclophosphamide-doxorubicin. Etoposide was chosen because its mechanism of action requires DNA synthesis, it frequently causes hair loss in the clinical setting, and it induces alopecia in the neonatal rat (24) . The cyclophosphamide-doxorubicin combination is highly alopecic and is frequently prescribed for patients with advanced metastatic breast cancer (25) . Rat pups were treated topically on the scalp with compound 4 before receiving etoposide or cyclophosphamide-doxorubicin. In animals treated on the scalp with 2.5 to 250 g of compound 4, hair protection was exclusively confined to the scalp (Fig. 4) . Thus, wholebody hair loss served as an internal control for the alopecia-inducing effects of etoposide. Protection of the hair was marked; compound 4 treatment protected 50% of the rats from etoposide-induced alopecia, with an additional 20% of the animals showing partial protection ( Table 1 ).
The histopathological profile of etoposide-treated rat skin was improved by compound 4 in a number of ways. Compound 4 treatment increased the number of viable hair follicles, increased the number of dermal papilla, reduced the level of inflammation, decreased the amount of cellular damage to the epithelium, reduced the thickening of the epidermis, and decreased the number of apoptotic cells in the hair follicle matrix (15). Moreover, 29 structural analogs of compound 4 produced similar efficacy in this model. Compound 4 treatment prevented hair loss on the scalp in 33% of the rats in the cyclophosphamide-doxorubicin model ( Table 1 ) (15).
The lack of toxicity of compound 4 on normal epithelium was corroborated by studies monitoring hair growth. Compound 4 (250 g) applied topically did not cause alopecia in either the human hair xenograft or the neonatal rat models. In addition, histopathological analysis of hematoxylin and eosin-stained rat skin sections from compound 4-treated animals did not reveal any abnormalities in comparison to vehicle-treat- ed controls. Topical formulations that lack DMSO and are suitable for human testing have been developed (26) .
The theoretical issue of antagonism of antitumor efficacy is addressed by regional delivery of the compound to the scalp and limited systemic drug exposure (15). Furthermore, drug combination studies of compound 4 with cytotoxic agents did not reveal evidence of tumor protection, either in colonyforming tumor survival assays in vitro or in a human colon xenograft tumor model in vivo (15). Finally, CDK2 inhibition may induce selective cell killing of tumor cells. Indeed, the killing of transformed cells by cell-permeable CDK2 inhibitory peptides suggests that CDK2 inhibitors have potential as antineoplastic agents (27) .
Although CIA is considered a reversible side effect, the traumatic visual reminder and the stigma of alopecia reinforces a sense of 3 ) were plated on 96-well plates and treated with compound 4 (12 M) for 24 hours before treatment with cytotoxic agents for 48 hours. After 72 hours total exposure time for compound 4, cells were fixed and stained with the sulforhodamine B protein-binding dye, and the optical density was determined at 562 nm to reflect the number of stained cells. Table 1 . Summary of compound 4 efficacy in the prevention of hair loss in the neonatal rat. The amount of hair present on rat scalp at day 21 was scored as follows: I, no hair; II, Ͻ50% hair; III, Ͼ50% hair; and IV, 100% hair. Because greater than 50% hair loss on a human scalp is required for a clearly noticeable cosmetic change, grade III and IV animals were categorized as responders, and grade II animals were categorized as partial responders. The total number of responders relative to the total number of animals studied, expressed as a percentage, was determined from nine experiments for the etoposide model and three experiments for the cyclophosphamide-doxorubicin model. Compound 4 efficacy data were analyzed by comparing percentages of drug-treated responders (III and IV ) and vehicle-treated responders. A 2 analysis of the composite data for the drug-treated and vehicle-treated groups was used to address experiment-to-experiment variability and to assess meaningful differences. The dosing schedule of compound 4 consisted of two doses, either at 4 and 2 hours or at 10 and 4 hours before cytotoxic therapy. helplessness and the perception that the patient may not survive his or her disease. On the basis of the evidence presented here, clinical trials in cancer patients to assess the efficacy of this approach to prevent CIA may be warranted. Rat pups (13 days of age, actively growing hair) were pretreated 4 hours and 2 hours (t ϭ Ϫ4 and Ϫ2 hours) with topical application of compound 4 (250 g; 50 l of 5 mg/ml DMSO) to the scalp, then injected with etoposide. Etoposide induced total alopecia within 1 week of administration. Hair was assessed and photographed on day 21. The protective activity was schedule dependent. Two applications, 4 hours and 2 hours before etoposide, were optimal for protection. Post-treatment schedules were ineffective in preventing hair loss. Shown are two animals from the untreated group (-etoposide, upper left panel, animals 1 and 2); two animals from DMSO-treated group (ϩ etoposide, upper right, animals 3 and 4), and five animals from compound 4-treated group (ϩ etoposide, lower panel, animals 5 to 9). Experiments were repeated at least nine times with five rats per experimental subgroup.
